BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 16945529)

  • 1. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
    Schott Y; Decker M; Rommelspacher H; Lehmann J
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5840-3. PubMed ID: 16945529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
    Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
    J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
    Rook Y; Schmidtke KU; Gaube F; Schepmann D; Wünsch B; Heilmann J; Lehmann J; Winckler T
    J Med Chem; 2010 May; 53(9):3611-7. PubMed ID: 20361801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A.
    Becher PG; Beuchat J; Gademann K; Jüttner F
    J Nat Prod; 2005 Dec; 68(12):1793-5. PubMed ID: 16378379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
    Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
    Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.
    Groner E; Ashani Y; Schorer-Apelbaum D; Sterling J; Herzig Y; Weinstock M
    Mol Pharmacol; 2007 Jun; 71(6):1610-7. PubMed ID: 17347320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
    Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
    Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors.
    Sheng R; Lin X; Zhang J; Chol KS; Huang W; Yang B; He Q; Hu Y
    Bioorg Med Chem; 2009 Sep; 17(18):6692-8. PubMed ID: 19692250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
    Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
    Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
    Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
    Szymański P; Janik A; Zurek E; Mikiciuk-Olasik E
    Pharmazie; 2011 Jun; 66(6):399-403. PubMed ID: 21699076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity.
    Siwicka A; Moleda Z; Wojtasiewicz K; Zawadzka A; Maurin JK; Panasiewicz M; Pacuszka T; Czarnocki Z
    J Pineal Res; 2008 Aug; 45(1):40-9. PubMed ID: 18284552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
    Tang H; Zhao HT; Zhong SM; Wang ZY; Chen ZF; Liang H
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2257-61. PubMed ID: 22341944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
    Camps P; Formosa X; Galdeano C; Muñoz-Torrero D; Ramírez L; Gómez E; Isambert N; Lavilla R; Badia A; Clos MV; Bartolini M; Mancini F; Andrisano V; Arce MP; Rodríguez-Franco MI; Huertas O; Dafni T; Luque FJ
    J Med Chem; 2009 Sep; 52(17):5365-79. PubMed ID: 19663388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibition activity of selected beta-carboline alkaloids on enzymes of acetylcholinesterase and butyrylcholinesterase.
    Krsková Z; Martin J; Dusek J
    Ceska Slov Farm; 2011 Jun; 60(3):125-31. PubMed ID: 21838142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.